DEVELOPMENT AND PARTIAL EVALUATION OF A RECOMBINANT VACCINE AGAINST Anaplasma marginale

SARLI, MACARENA; NOVOA, MARÍA B.; MAZZUCCO, MATILDE N.; THOMPSON, CAROLINA S.; DE ECHAIDE, SUSANA T.; ECHAIDE, IGNACIO E.; PRIMO, MARÍA E.

Buenos Aires

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

Sociedades de Biociencias

Anaplasma marginale is an intraerythrocytic bacteria that causebovine anaplasmosis, disease characterized by high lethality inadults. The disease is in expansion and has become a seriousthreat to cattle industry. The drawbacks of the currently used A. centralelive vaccine, produced in splenectomized calves, boosted thesearch of safer, more efficient and cost-effective immunogens. Theaim of this preliminary work was to evaluate the humoral and cellularimmune responses generated by the inoculation of the recombinantform of five subdominant and surface exposed A. marginale proteins,members of the type IV secretion system. VirB9.1, VirB9.2,VirB10, VirB11 and Et-Tu proteins were cloned and expressed inEscherichia coli. Twenty Holstein steers, two years old, were randomlyclustered into four groups (G) of five steers each. GA andGB were immunized with a cocktail of 50 μg of each recombinantprotein (rP) in Quil-A® or Montanide® adjuvants, respectively. GCand GD (controls) were inoculated with Quil-A or Montanide adjuvants,respectively. Steers received four inoculations within threeweekinterval. An indirect ELISA, and a lymphocyte proliferationassay (LPA) was standardized to evaluate the humoral and cellularimmune response against the five rP. The production of rVirB9.1/9.2was higher (25 mg/L) than that produced by the remaining three rP(